NCT00367783View on ClinicalTrials.gov

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

April 30, 2007

Conditions
Obesity
Interventions
DRUG

CP-741,952

Trial Locations (5)

28211

Pfizer Investigational Site, Charlotte

48105

Pfizer Investigational Site, Ann Arbor

49007

Pfizer Investigational Site, Kalamazoo

78229

Pfizer Investigational Site, San Antonio

10021-7903

Pfizer Investigational Site, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00367783 - Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity | Biotech Hunter | Biotech Hunter